331 related articles for article (PubMed ID: 32689862)
21. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Cicero AFG; Fogacci F; Cincione I
Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
[No Abstract] [Full Text] [Related]
22. Updated clinical evidence and place in therapy of bempedoic acid for hypercholesterolemia: ANMCO position paper.
Colivicchi F; Di Fusco SA; Scicchitano P; Caldarola P; Murrone A; Valente S; Urbinati S; Roncon L; Amodeo V; Aspromonte N; Cipriani M; Domenicucci S; Francese GM; Imazio M; Scotto di Uccio F; Di Lenarda A; Gulizia MM; Gabrielli D
J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):162-171. PubMed ID: 32842050
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
[TBL] [Abstract][Full Text] [Related]
24. Bempedoic Acid: A New Tool in the Battle Against Hyperlipidemia.
Powell J; Piszczatoski C
Clin Ther; 2021 Feb; 43(2):410-420. PubMed ID: 33384162
[TBL] [Abstract][Full Text] [Related]
25. Effects of bempedoic acid on markers of inflammation and Lp(a).
Reddy S; Deoker A
Curr Opin Cardiol; 2024 Jul; 39(4):280-285. PubMed ID: 38456474
[TBL] [Abstract][Full Text] [Related]
26. Bempedoic acid as adjunct for traditional lipid-lowering therapy in patients with hyperlipidaemia.
Schimmenti C; Sucato V; Manzone E; Cancellieri G; Mortillaro F; Novo G; Galassi AR; Venturella F
Coron Artery Dis; 2021 Jun; 32(4):340-344. PubMed ID: 33229935
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: A meta-analysis and a systematic randomized controlled trial review.
Li Y; Gao H; Zhao J; Ma L; Hu D
PLoS One; 2024; 19(1):e0297854. PubMed ID: 38277431
[TBL] [Abstract][Full Text] [Related]
28. ETC-1002: a future option for lipid disorders?
Nikolic D; Mikhailidis DP; Davidson MH; Rizzo M; Banach M
Atherosclerosis; 2014 Dec; 237(2):705-10. PubMed ID: 25463109
[TBL] [Abstract][Full Text] [Related]
29. Role of Bempedoic Acid in Dyslipidemia Management.
Kelly MS; Sulaica EM; Beavers CJ
J Cardiovasc Pharmacol; 2020 Oct; 76(4):376-388. PubMed ID: 32732494
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials.
Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC
J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials.
Venkatraman S; Das S; Eerike M; Cherian JJ; Bagepally BS
Eur J Clin Pharmacol; 2023 Nov; 79(11):1453-1463. PubMed ID: 37672112
[TBL] [Abstract][Full Text] [Related]
32. A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Bempedoic Acid.
Asbeutah AAA; Asbeutah SA; Abu-Assi MA
Am J Cardiol; 2020 Oct; 132():166-168. PubMed ID: 32713651
[No Abstract] [Full Text] [Related]
33. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
[TBL] [Abstract][Full Text] [Related]
34. Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies.
Cicero AFG; Pontremoli R; Fogacci F; Viazzi F; Borghi C
Drug Saf; 2020 Aug; 43(8):727-736. PubMed ID: 32358698
[TBL] [Abstract][Full Text] [Related]
35. Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy.
Ballantyne CM; McKenney JM; MacDougall DE; Margulies JR; Robinson PL; Hanselman JC; Lalwani ND
Am J Cardiol; 2016 Jun; 117(12):1928-33. PubMed ID: 27138185
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
[TBL] [Abstract][Full Text] [Related]
37. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
[TBL] [Abstract][Full Text] [Related]
38. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
Paton DM
Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials.
Shapiro MD; Taub PR; Louie MJ; Lei L; Ballantyne CM
Atherosclerosis; 2023 Aug; 378():117182. PubMed ID: 37517922
[TBL] [Abstract][Full Text] [Related]
40. Clinical Efficacy and Safety of Bempedoic Acid in High Cardiovascular Risk Patients: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Uddin N; Syed AA; Ismail SM; Ashraf MT; Khan MK; Sohail A
Curr Probl Cardiol; 2023 Dec; 48(12):102003. PubMed ID: 37516330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
